232
Last Update Posted: 2016-05-06
Recruiting has ended
All Genders accepted | 22 Years-51 Years |
0 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Alternate Day Buprenorphine Administration, Phase IX - 14
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
Eligibility
Relevant conditions:
Opioid-Related Disorders
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov